BioCentury
ARTICLE | Company News

Poniard cancer news

May 23, 2011 7:00 AM UTC

Poniard disclosed in its 1Q11 earnings that it will require additional capital to continue operations through 4Q11. Last year, Poniard said it hired Leerink Swann to seek strategic alternatives, including financing, merger, sale or partnership, and plans to restructure and would reduce headcount by 10 (45%) to 12. At March 31, the company had $5.5 million in cash and a three-month operating loss of $3.2 million. ...